Primary Biliary Cirrhosis - Pipeline Review, H2 2013, New Report Launched

Primary Biliary Cirrhosis - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Primary Biliary Cirrhosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis. Primary Biliary Cirrhosis - Pipeline Review, Half Year is built using data and information sourced from report proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.

Scope

• A snapshot of the global therapeutic scenario for Primary Biliary Cirrhosis.
• A review of the Primary Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Primary Biliary Cirrhosis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 73 pages, 23 Tables and 15 Figures “Primary Biliary Cirrhosis - Pipeline Review, H2 2013” report provide Primary Biliary Cirrhosis Overview, Therapeutics Development, Pipeline Products for Primary Biliary Cirrhosis - Comparative Analysis, Therapeutics Development, Drug Profiles, Product Description, Diseases, Appendix and the report cover 7 companies - Johnson & Johnson, GlaxoSmithKline plc, AlbireoPharma, NovImmune SA, Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Lumena Pharmaceuticals, Inc.

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/primary-biliary-cirrhosis-pipeline-review-h2-2013

Find All Pharma and Healthcare Reports at: 

http://www.marketresearchreports.com/pharma-healthcare